< Back to previous page
Researcher
Patrik Verstreken
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Neurological and neuromuscular diseases
Affiliations
- Research Group Molecular Neurobiology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Responsible
From1 Jan 2008 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Member
From1 Jan 2017 → Today - VIB-KU LEUVEN CENTER FOR BRAIN & DISEASE RESEARCH (Research Center)
Responsible
From1 Jan 2017 → Today - VERSTREKEN LAB (Research group)
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From1 Apr 2009 → 31 Dec 2016
Projects
1 - 10 of 63
See also Patrik Verstreken for projects of Flanders Institute for Biotechnology.
Here below the projects of KU Leuven.
- Targeting synaptic dysfunction in dementiaFrom1 Oct 2025 → TodayFunding: Fund Recuperation Fiscal Exemption, BOF - projects
- The impact of intracranial pressure on neuronal healthFrom29 Sep 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Disruption of vesicle transport as a pathogenic mechanism in Parkinson's diseaseFrom1 Jan 2025 → TodayFunding: Other federal public and semi-governmental institutions
- Antisense oligonucleotides as therapeutics for Autosomal Dominant Alzheimer’s DiseaseFrom1 Jan 2025 → TodayFunding: Other federal public and semi-governmental institutions
- Microglia and Synaptic Plasticity: Uncovering Hibernation Mechanisms to Combat NeurodegenerationFrom7 Oct 2024 → TodayFunding: FWO fellowships
- Identification of synaptic targets for the treatment of tauopathiesFrom1 Oct 2024 → TodayFunding: FWO junior postdoctoral fellowship
- Sleep-like activity on multielectrode array (MEA)-chip for Parkinson's disease (SLAM-PD).From1 Oct 2024 → 31 Jul 2025Funding: FWO senior postdoctoral fellowship
- Extreme synaptic plasticity: mechanisms of synapse loss and regeneration during hibernationFrom16 Sep 2024 → TodayFunding: FWO fellowships
- Physiological role of Tau in sleepFrom10 Jul 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Tau-dependent synaptic remodeling in health and diseaseFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
Publications
11 - 20 of 157
See also Patrik Verstreken for publications of Flanders Institute for Biotechnology.
Here below the publications of KU Leuven.
- Neuronal identity defines a-synuclein and tau toxicity(2023)Published in: NeuronISSN: 0896-6273Issue: 10Volume: 111
- EndophilinA-dependent coupling between activity-induced calcium influx and synaptic autophagy is disrupted by a Parkinson-risk mutation(2023)Published in: NeuronISSN: 0896-6273Issue: 9Volume: 111Pages: 1402 - +
- Neurodegeneration cell per cell(2023)Published in: NeuronISSN: 0896-6273Issue: 6Volume: 111Pages: 767 - 786
- Tyrosyl-tRNA synthetase has a noncanonical function in actin bundling(2023)Published in: Nature CommunicationsISSN: 2041-1723Issue: 1Volume: 14
- Parkinsonism mutations in DNAJC6 cause lipid defects and neurodegeneration that are rescued by Synj1(2023)Published in: npj Parkinsons DiseaseISSN: 2373-8057Issue: 1Volume: 9
- A reference human induced pluripotent stem cell line for collaborative studies(2022)Published in: Cell Stem CellISSN: 1934-5909Issue: 12Volume: 29Pages: 1685 - +
- Tau, synapses and brain disease(2022)
- Nano-positioning and tubulin conformation contribute to axonal transport regulation of mitochondria along microtubules(2022)Published in: Proceedings of the National Academy of Sciences of the United States of AmericaISSN: 0027-8424Issue: 45Volume: 119
- Do we still need animals? Surveying the role of animal-free models in Alzheimer's and Parkinson's disease research(2022)Published in: EMBO JournalISSN: 0261-4189Issue: 6Volume: 41
- Synaptic proteostasis in Parkinson's disease(2022)Published in: Current Opinion in NeurobiologyISSN: 0959-4388Volume: 72Pages: 72 - 79
Patents
1 - 10 of 10
- Oligonucleotides for modulating synaptogyrin-3 expression
- Compounds for treatment of intractable epilepsy and doors syndrome
- Screening method for synaptogyrin-3 inhibitors
- Targeting synaptogyrin-3 in tauopathy treatment
- Targeting synaptogyrin-3 in tauopathy treatment
- Means and methods for treatment of early-onset parkinson's disease
- Means and methods for treatment of early-onset parkinson's disease
- Targeting synaptogyrin-3 in tauopathy treatment
- Compounds for treatment of intractable epilepsy and doors syndrome
- Restoring phosphorylation of a novel pink1 substrate to treat parkinson's disease